The Global Market for Cystic Fibrosis Therapeutics is Projected to Reach US$9 Billion by 2022

Introduction of Novel Drugs Designed to Address High Unmet Patient Needs to Drive the Cystic Fibrosis Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Cystic Fibrosis market. The global market for Cystic Fibrosis Therapeutics is projected to reach US$9 billion by 2022, driven by improving diagnosis rate, increased research activity, strong drug development pipeline and expected launch of novel treatments designed to address the high unmet patient needs.

Cystic Fibrosis (CF), a rare disease, is a life-limiting genetic disorder. CF is a genetic disorder of the exocrine glands that affects ion/water transport across cells, resulting in accumulation of thick mucus in the respiratory and digestive systems leading to infections. Progressive impairment of lung function due to build-up of thick mucus is the leading cause of mortality in CF patients. The market is expected to expand significantly over the coming years given the successful launch of novel and enhanced drug formulations or therapies including new mucolytic drugs, pancreatic enzyme replacement drugs, anti-inflammatory drugs, and drugs targeting genetic CFTR defects as they emerge from the pipeline. Despite the introduction of various advanced medications in recent years, cystic fibrosis remains a disease with high unmet medical needs. Current treatment methods for cystic fibrosis are usually expensive, moderately effective, difficult to administer, and requires aggressive therapy and hospitalization. At present, several companies are progressing towards the development of mutation-specific therapy for a specific group of patients with CF. Significant advancements have been made towards the development of therapies that specifically act against Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein abnormalities. Most of the research and treatment initiatives are focused on three groups of drugs, namely potentiators, correctors and read-through agents. Rigorous research is also underway to advance gene therapy in the treatment of cystic fibrosis. The future is also expected witness the launch of novel antibiotics, lung-transport drugs, nutritional supplements, pancreatic enzyme products, and drugs intended for mucus treatment.

As stated by the new market research report on Cystic Fibrosis, the United States represents the largest market worldwide in. Rest of World, comprising Asia-Pacific, Latin America, the Middle East and Africa, ranks as the fastest growing market with a CAGR of 23.7% over the analysis period. The growth in these markets is led by growing population and rising healthcare needs; rising diagnosis of CF coupled with better healthcare awareness; improved medical services, and enhanced pharmaceutical R&D.

Major players covered in the report include AbbVie Inc., Galapagos NV, Genentech, Gilead Sciences Inc., Novartis AG, and Vertex Pharmaceuticals Incorporated.

The research report titled "Cystic Fibrosis: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of disease overview, market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets, such as the US, Canada, Europe, and Rest of World.  

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.